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Abstract
Background: A rise in gastrointestinal (GI) adverse events (AEs) and a decline in bone mineral density (BMD) was 
observed in patients previously tolerant to brand alendronate shortly after generic versions were introduced in July 
2005 to the Canadian market. The objective of our study was to quantify changes in AE rates and BMD scores, as well as 
associated alendronate discontinuation among patients before and after switch from brand to generic alendronate.
Methods: A chart review of postmenopausal women 50 years of age and older between 2003 and 2007 was 
conducted in two specialized tertiary care referral centers. Patients on alendronate both before and after July 2005 
were included. The change in the number of AEs, changes in BMD and associated alendronate discontinuation was 
compared before and after the switch from brand to generic alendronate.
Results: 301 women with an average age of 67.6 years (standard deviation (SD) = 9.5) had a total of 47 AEs between 
July 2003 and December 2007 that resulted in discontinuation of the medication. There was a significant increase in 
the rate of AEs per patient-months-at-risk from 0.0001 before to 0.0044 after October 2005 (p < 0.001). The most 
common AEs were GI in nature (stomach pain, GI upset, nausea, and reflux). In addition, 23 patients discontinued 
alendronate due to BMD reduction after January 2006. In these patients, BMD scores were significantly reduced from 
their prior BMD measures (change of -0.0534, p < 0.001 for spine BMD and change of -0.0338, p = 0.01 for femur BMD). 
Among patients who discontinued due to BMD reduction, BMD was stable in the period prior to January 2006 (change 
of -0.0066, p = 0.5 for spine BMD and change of 0.0011, p = 0.9 for femur BMD); however, testing for reduction after 
January 2006 in BMD measures (one-sided T-test) revealed there was a significant reduction in BMD scores for both 
anatomic sites (change of -0.0321, p = .005 for spine, change of -0.0205, p = 0.05 for femur).
Conclusions: Patients who were previously stable on doses of brand alendronate experienced an increase in AEs 
causing discontinuation after introduction of automatic substitution to generic alendronate. In addition, reductions in 
BMD were observed in some patients who had stable BMDs before January 2006. Given the substantial increase in AEs, 
generic alendronate may not be as well tolerated as brand alendronate.
Background
O s t e o p o r o s i s  i s  c o m m o n  i n  C a n a d a  a f f e c t i n g  1 6 %  o f
women and 6.6% of men over 50 years of age [1]. Despite
the availability of a number of therapeutic options, many
patients with fragility fracture do not undergo osteoporo-
sis management and are at high risk for subsequent frac-
tures [2-4].
Alendronate sodium has been extensively used for the
treatment of osteoporotic patients in Canada. Generic
alendronate versions were introduced in Canada in July
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2005. As a result of automatic substitution implemented
at the pharmacy level, over 80% of private and public plan
p a t i e n t s  w e r e  s w i t c h e d  f r o m  b r a n d  t o  g e n e r i c  a l e n -
dronate within two months. Typically, patients would not
have been notified of the conversion. Shortly afterwards
we noticed an increase in the frequencies of gastrointesti-
nal (GI) adverse events (AEs) and bone mineral density
(BMD) declines, in those who had previously been stable
on brand alendronate.
The potential for an increased risk of GI AEs has been
noted with brand versions of alendronate sodium, espe-
cially when taken incorrectly [5]. It is likely that similar
risks are associated with generic versions, however clini-
cal trials examining the GI tolerability of generic versions
of alendronate compared to the original formulations are
not available. The objective of this retrospective chart
review was to quantify the number and type of AEs, and
the proportion of AEs which led to discontinuation
among patients before and after the switch from brand to
generic alendronate.
Methods
Study design
Data were obtained from an analysis of patient charts
from two specialized tertiary care referral centers in
Hamilton, Ontario. Ethics approval for the study was not
required as it was conducted as a self-audit of private
practices. Patients were screened in alphabetical order
from a list of all female clinic patients using the following
inclusion criteria: age 50 years or older between 2003 and
2007, post-menopausal, confirmed osteoporosis and con-
tinuous treatment with alendronate sodium 10 mg daily
or 70 mg once-weekly doses before and after July 2005.
Data abstraction was conducted by one member of the
clinical staff and was entered into a centrally maintained
database using anonymous patient identifiers.
The following data were collected:
1. Visit dates
2. AEs noted within the patient chart as possibly
related to the bisphosphonates under use. An initial
list of AEs was developed from published clinical tri-
als of original alendronate (alendronate sodium) and
supplemented based on clinical experience with bis-
phosphonates therapy [6-9]. AEs captured included
specific and general GI complaints (i.e., stomach
pain/upset, GI upset, nausea, reflux, heartburn, bloat-
ing, constipation, diarrhea, rectal bleeding, bowel
problems, perforated diverticulum, stomach ulcer), as
well as unspecified trouble with apo-alendronate,
chest pain, loss of appetite, general feeling of being
unwell, anemia, rash, shortness of breath, bone pain,
arthralgias, flank pain, and leg cramping.
3. BMD at femoral neck and vertebral sites. BMD
testing was conducted annually in most patients.
BMD measurements were made using a Hologic Del-
phi QDR-W machine.
4. Discontinuation and initiation of osteoporosis
treatments.
5. Patient age
6. Concomitant use of calcium, vitamin D, estrogen,
proton pump inhibitors, non-steroidal anti-inflam-
matory drugs (NSAIDs) and H2 receptor antagonists
Analysis
The switch from brand to generic alendronate occurred
at the pharmacy level in July 2005 but since prescriptions
are usually prescribed for a three- month period, expo-
sure to both brand and generic alendronate would be
expected between July 1, 2005 and October 1, 2005. As
some AEs in this period may have been related to brand
alendronate, we treated AEs during this three-month
period as applicable to brand alendronate, which could
bias results against the hypothesis of greater AEs with
generic alendronate.
To consider equal time for each exposure period, we
selected two time periods: July 1, 2003 to September 30,
2005, and; October 1, 2005 to December 31, 2007. The
number of AEs resulting in discontinuation of treatment
was compared in the two study periods. To take into
account the effect of duration of treatment on develop-
ment of AEs, the rate of AEs was calculated per patient-
months-at-risk. The rate of AEs per patient-months-at-
risk was compared between the two study periods.
The total number of AEs and patient-time-at-risk were
compared using chi-squared test. When evaluating BMD
changes, January 1, 2006 was used as the threshold
between periods as it may take a minimum of six months
(from the time of switch) for changes in BMD to appear
in bone scans. Therefore such changes in BMD observed
between July 1, 2005 and January 1, 2006 would be most
likely related to treatment with brand alendronate. Two
analyses were conducted on BMD. First, for those visits at
which discontinuation of alendronate was noted due to a
decline in BMD, the BMD data were analyzed to confirm
a decline in BMD, by comparing BMD at the alendronate
discontinuation visit to the preceding BMD measure-
ment. Since the differences in BMD measures between
the two visits followed a normal distribution, a two-tailed
paired t-test was employed for this comparison. Second,
for those occurrences where two or more BMD measure-
ments were available before January 2006, the stability of
BMD was examined to test the possibility of the effect of
aging on BMD differences. For this purpose, three con-
secutive BMD measures were selected: the two BMD
measurements immediately preceding January 2006 and
the first BMD measurement occurring after 2006. The
change in the first two measures (both occurring before
January 2006) and the change between the last BMDGrima et al. BMC Musculoskeletal Disorders 2010, 11:68
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measure before January 2006 and the first BMD measure
after January 2006 were calculated. To test stability of
BMD scores in the two time periods, the average change
in BMD scores was compared to 0 (no change). Again,
since BMD differences between compared measurements
followed a normal distribution and because significant
reduction was only hypothesized, one-sided T-tests were
employed.
The data was managed and the analyses were per-
formed using SPSS version 16.0. Analyses were indepen-
dent of the sponsor based on a data analysis plan
established prior to study start.
Results
A total of 301 patients were included in the study of AEs.
Table 1 shows the baseline characteristics and the covari-
ate distribution in this study population. Patients ranged
in age from 50.62 to 89.23 years old, with a mean age of
67.6 (SD = 9.5) years at the time of the switch. Use of aspi-
rin/NSAIDs, calcium, vitamin D, and estrogen was simi-
lar in the two time periods (Table 1). A summary of the
type and frequency of observed AEs is shown in Table 2.
The most frequent AEs were GI in nature (stomach pain,
GI upset, nausea, and reflux). There were no deaths or
laboratory AEs in the study. Figure 1 shows the number
of AEs resulting in discontinuation over the study peri-
ods. The increase in the number of AEs after July 2005 is
notable. The total number of patient-months-at-risk
(total months patients were on treatment of interest)
between July 1, 2003 and October 1, 2005 was greater
than that between October 2005 and December 2007
(20,492 vs. 9,929) due to the greater number of discontin-
uations in the latter time period. The rate of AEs per
patient was significantly higher in the second time period
(0.0001 vs. 0.0044 per patient-months-at-risk). The rate
was statistically significantly higher after October 1, 2005
(p < 0.001). Table 3 summarizes these results.
Figure 2 shows the proportion of AEs that resulted in
discontinuation in the two study periods. Rate of AEs was
greater in the second period when patients were on
generic alendronate compared to in the first period when
patients were on original alendronate. AEs were severe
enough to warrant discontinuation of alendronate in over
21% of cases before October 1, 2005 and 79% of cases
after October 1, 2005 (Figure 2).
Discontinuation of alendronate due to BMD reduction
after January 2006 occurred in 23 patients. The average
BMD score for those who discontinued alendronate after
January 2006 was 0.756 g/cm2 (SD 0.120) and 0.664 g/cm2
(SD 0.130) for spine and femur respectively, while in their
previous measurements these patients had average BMD
scores of 0.813 g/cm2 (SD 0.138) and 0.699 g/cm2 (SD
0.129) for spine and femur respectively. This reduction in
BMD scores was significant (p < 0.001 for change in spine
BMD score and p = 0.01 for change in femur BMD score).
Table 4 summarizes these results.
To test the possibility that the decline in BMD measure-
ments in these patients were due to aging, we compared
the stability of BMD before January 2006 and after Janu-
ary 2006. Among patients who discontinued due to BMD
reduction and who had at least two other BMD measures
before 2006 (n = 11 for spine and n = 9 for femur), we
found that BMD was stable in the period prior to January
2006 (p = 0.5 for change of -0.0066 in spine BMD score
and p = 0.9 for change of 0.0011 in femur BMD score)
(see Figure 3). However, testing for reduction in BMD
after January 2006 (one-sided T-test) revealed a signifi-
cant reduction in BMD scores for both anatomic sites (p
= .005 for change of -0.0321 in spine BMD, p = 0.05 for
change of -0.0205 in femur BMD).
Discussion
Many generic copies of alendronate sodium are available
on the provincial formulary in Ontario, Canada, but not
Table 1: Baseline characteristics of the study population
Characteristic First Period (July 2003 to 
September 2005)
Second Period (October 
2005 to December 2007)
Difference (p value of the 
test of difference)
Mean age (years) 65.6 (9.5) 67.6 (9.5) 2 (<0.0001)
NSAID use (%) 31% 25% 6% (0.08)
Vitamin D use (%) 81% 86% 5% (0.1)
Calcium use (%) 80% 75% 5% (0.17)
Estrogen use (%) 6% 9% 3% (0.16)
SD: standard deviation; NSAID: non-steroidal anti-inflammatory drugGrima et al. BMC Musculoskeletal Disorders 2010, 11:68
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Table 2: Frequency of different AEs in the study population
AEs Frequency of occurrence Percent of all AEs
Stomach Pain/Upset 16 22.86
GI Upset 11 15.71
Nausea 5 7.14
Reflux 5 7.14
Heartburn 4 5.71
Bloating 3 4.29
Constipation 3 4.29
Trouble with Apo-Alendronate 3 4.29
Chest Pain 2 2.86
Diarrhea 2 2.86
Loss of Appetite 2 2.86
Rectal Bleeding 2 2.86
Generally Unwell 2 2.86
Stomach Ulcer 1 1.43
Anemia 1 1.43
Rash 1 1.43
Perforated Diverticulum 1 1.43
Shortness of Breath 1 1.43
Bone Pain 1 1.43
Bowel Problems 1 1.43Grima et al. BMC Musculoskeletal Disorders 2010, 11:68
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all of these formulations have been fully characterized in
terms of therapeutic equivalence or safety/tolerability
profile relative to original alendronate. Of particular rele-
vance is the GI tolerability of the various formulations, as
bisphosphonates in general have the potential to cause GI
irritation and implications may exist for individualizing
treatment. This study found that introduction of generic
alendronate was associated with an increase in GI AEs
leading to alendronate discontinuation and occurrences
of discontinuation related to reduced BMD.
Oral bisphosphonates are poorly absorbed in the GI
tract [10]. They have been associated with an increased
risk of upper GI AEs, especially when taken incorrectly
[5]. While the upper GI tolerability profile of the bisphos-
phonate, alendronate sodium (Fosamax) was similar to
that of placebo in controlled clinical trials [6,11], generic
formulations have not been studied as extensively and it
is unclear whether they differ in GI tolerability from the
original formulation [12,13]. Based on the belief that GI
s i d e  e f f e c t s ,  i n  p a r t i c u l a r  e s o p h a g e a l  i r r i t a t i o n ,  r e s u l t
from events that occur prior to absorption of the drug
into the GI tract, it has been postulated that the length of
time required for a given formulation to disintegrate and
dissolve may impact the tendency of the drug to cause
irritation [12]. In vitro studies of various generic formula-
tions of alendronate have demonstrated variations in dis-
integration and dissolution profiles as well as potential
for esophageal bioadhesion, and have suggested that
these differences may influence bioavailability, pharma-
cokinetics, efficacy, and tolerability [12,14-16].
In one study [12], several generic copies disintegrated
two- to ten-fold faster than brand Fosamax. Other copies
disintegrated at least five-fold slower than Fosamax. Yet
another generic did not fall into either category but
exhibited potentially large inter- and intra-lot variability.
In another study [17], the mean disintegration times of
the generic alendronate tablets ranged from 14 s to 342 s.
The mean disintegration time of the Fosamax tablets
ranged from 43 s to 78 s. Six of twenty-six generic tablets
had very rapid disintegration times which were two to
three times more rapid than Fosamax [17]. These results
show that important differences may exist between Fosa-
max and its copies with regard to bioavailability, pharma-
cokinetics, and clinical efficacy and safety profiles. It is
possible that rapid disintegration may increase esopha-
geal drug exposure and possible toxicity leading to
decreased upper GI tolerability. Slower disintegration
m a y  p la c e  t h e  d ru g  i n  c o n t a ct  wi t h  f ood  o r  bev e r a g es
severely reducing its bioavailability, reducing the efficacy
as bisphosphonates [18]. Additional testing is warranted
to evaluate the clinical safety and efficacy of these copies.
Our study also raises the possibility that disintegration
profile led to an increase in AEs; the majority of which
resulted in discontinuation. In addition, the BMD data
Arthralgias 1 1.43
Flank Pain 1 1.43
Leg Cramping 1 1.43
Total 70 100.00
AE: adverse event; GI: gastrointestinal
Table 2: Frequency of different AEs in the study population (Continued)
Table 3: Total number of patients, years at risk and AEs leading to discontinuation
July/03-Oct/05 Oct/05-Dec/07
Total number of patients 301 301
Number of AEs resulting in 
discontinuation
34 4
Number of patient months at risk 20492 9929
Rate of AEs per patient-months-at-risk 0.0001** 0.0044**
AE: adverse event; **Difference between two periods is significant at p < 0.001 levelGrima et al. BMC Musculoskeletal Disorders 2010, 11:68
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indicate that differences in effectiveness between brand
and generic alendronate may also exist, as 7% of patients
(23 out of 301) discontinued generic alendronate due to
significant reduction in their BMD scores, which had pre-
viously been stable. These results are supported by a
recent analysis of Canadian administrative claims data,
which found that the risk of discontinuation doubled in
patients initiated with generic alendronate compared to
patients started on branded alendronate [19]. We were
unable to find published evidence that there is a common
trend for discontinuation to be higher in patients using a
generic version of a product; however the literature in
this area is limited [20,21].
In addition, a recent chart review provides support to
our findings. In a study by Ringe and Möller 2009, the
generic alendronate was found to have lower persistence,
greater GI AEs and lower increases in BMD compared to
brand alendronate and risedronate. The chart review
studied three contemporaneous cohorts of patients initi-
ated on each of the three therapies [22].
Several limitations of the study are related to the retro-
spective and non-randomized design. To avoid preferen-
tially selecting those patients who experienced AEs with
generic alendronate, we screened all female patients in
the clinic and selected all patients who were continuously
treated with alendronate before and after July 2005.
Socio-demographic differences may have been present,
automatic substitution occurring more frequently in
lower income patients with a greater number of co-mor-
bidities. We were unable to test this hypothesis; however
given the policy of automatic substitution for public plan
patients, which include all patients over 65 years, this bias
is unlikely.
With a retrospective chart review there exists the possi-
bility that a systematic difference between the two peri-
ods could account for the changes in the outcome. To our
Figure 1 Number of AEs resulting in discontinuation over the study periods (3 months interval). AE: adverse event.
Figure 2 Number of AEs with and without discontinuation in the 
two study periods. AE: adverse event.
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knowledge, in the period of this study, no other changes
that could have a negative effect on patients' BMD
occurred. However, we are not able to completely rule out
the possibility of period effect by factors not measured in
this study. As with all measurements that occur over
time, there is also the possibility of measurement error in
BMD over time. However, it seems improbable that the
error happened in a systematic manner that would bias
against generic alendronate. Changes in BMD technology
may have occurred at measurement sites during the
study; however, most of the patients were studied using
the same machine in most of their measurements. Such
non-systematic measurement error likely introduced
noise into the dataset which could have made detection
of differences in BMD measures more difficult but it is
unlikely to have biased the results.
In summary, among non-Fosamax formulations of
alendronate, variation has been observed in terms of the
rates at which they disintegrate and dissolve, and it has
been suggested that this variation may correlate with
variations in GI tolerability [12]. Several examples of
mechanisms by which a causal relationship may exist
have been reviewed [12,14,17], including the supposition
that rapid disintegration could increase oral and esopha-
geal mucosal exposure to active drug, thereby increasing
the likelihood of irritation. Conversely, characteristics
such as tablet shape and coating may delay esophageal
transit and increase the risk of pill esophagitis, which may
in turn be exacerbated by a formulation with a longer dis-
integration/dissolution time [12,14]. Currently, however,
data directly evaluating the potential associations
between variable disintegration profiles and degree of
gastric irritation are scarce.
Conclusions
Patients who were previously stable on doses of brand
alendronate experienced an increase in AEs causing dis-
continuation after introduction of automatic substitution
to generic alendronate. In addition, reductions in BMD
were observed in some patients who had stable BMDs
before January 2006. Our study suggests that there may
be differences in both tolerability and effectiveness
between brand and generic alendronate. Further study is
warranted.
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Table 4: Comparison of BMD measures (g/cm2) resulting in discontinuation to the previous measurement (n = 23 for spine 
and n = 19 for femur)
BMD Score Measure after January 2006 
resulting in discontinuation (g/cm2)
Prior measure (g/cm2) Difference (p value of the 
test of difference)
Spine 0.756 0.813 -0.0534 (<0.001)
Femur 0.664 0.699 -0.0338 (0.01)
BMD: bone mineral density
Figure 3 Comparison of the change in BMD scores over time. 
BMD: bone mineral density.
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